Researchers at Monash University in Melbourne, Australia, have uncovered the hidden code governing how genetic mutations affect RNA splicing and result in disease. The researchers were able to identify the specific mutations that cause changes in RNA splicing, Sureshkumar Balasubramanian, the lead researcher at Monash University’s School of Biological Sciences, told BioWorld. Read More
French VC Andera Partners has reached the first close of its Biodiscovery Fund 7 at more than €300 million (US$349 million) and says it is on track to surpass the size of the previous fund, which closed at €456 million during the pandemic-driven boom of 2021. Read More
Corsera Health Inc. has filed a clinical trial notification (CTN) seeking to initiate a phase I trial of COR-1004 in New Zealand. COR-1004 is a novel investigational subcutaneously administered siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce LDL cholesterol (LDL-C). Read More
Microbiotix Co. Ltd. has obtained IND approval from the Korean Ministry of Food and Drug Safety (MFDS) for MP-101, a bacteriophage therapy for patients with acute pneumonia. A phase I study in adult patients with Pseudomonas aeruginosa-induced pneumonia is expected to enroll its first patient within the year. Read More
Forx Therapeutics AG presented data on their PARG inhibitor – FORX-428 – for the treatment of cancer. FORX-428 is a highly potent, selective and orally bioavailable PARG inhibitor that showed strong and reversible binding to the catalytic domain of the human PARG enzyme. Read More
What trends in life sciences have defined the last three decades? BioWorld Editor Nuala Moran picks monoclonal antibodies as the most significant. “They are the cornerstone around which medical biotechnology as a sector has been built.” Read More
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus and rheumatoid arthritis. Read More
Revolution Medicines Inc. has developed and presented data for their KRAS codon 13-targeting compound, RMC-8839, for treating non-small-cell lung cancers. Read More
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer. Read More
MicroRNAs (miRNAs) play key roles in cancer development by regulating genes involved in cell growth, differentiation, invasion, metastasis and angiogenesis. Because their expression patterns differ across tumor types and stages, miRNA profiles hold strong potential as noninvasive diagnostic and prognostic biomarkers. Read More
Scientists at Wuxi XDC (Shanghai) Co. Ltd. and Wuxi XDC Singapore Pvt Ltd. have divulged antibody-drug conjugates comprising antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of cancer. Read More
Shenzhen Newrosetta Biosciences Co. Ltd. has described deuterated derivatives of AF-DX 116 acting as muscarinic M2 receptor antagonists reported to be useful for the treatment of myopia. Read More
The natural product diterpene andrographolide, from Andrographis paniculata (‘creat’ or ‘green chiretta’), shows promising antitumor activity, so researchers from Nanjing Tech University and collaborators in mainland China and Hong Kong derivatized it by enlarging the six-membered decalin ring at position 3 to generate a seven-membered ring or by annulating the decalin at positions 3 and 19 through fusion with isoxazole. Read More
